Reproducibility study of the pharmacokinetics of amikacin, gentamicin and tobramycin; a three-way crossover study.
The hypothesis that the pharmacokinetics of amikacin are more predictable than those of gentamicin or tobramycin was studied. In a three-way crossover design 58 volunteers received 7.5 mg/kg amikacin by iv infusion and either 1.5 mg/kg or 1 mg/kg gentamicin and tobramycin. The mean half-life and mean serum concentration at 1 h for each drug was determined. No consistent significant difference was found between the pharmacokinetics of amikacin and the other two drugs.
D000583:Amikacin / Q000378:metabolism*; D001419:Bacteria / Q000187:drug effects; D005839:Gentamicins / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D014031:Tobramycin / Q000378:metabolism*
D005839:Gentamicins; D007612:Kanamycin; D000583:Amikacin; D014031:Tobramycin